Amgen 3Q profit jumps 24 pct. on stronger sales

October 22, 2013 by Linda A. Johnson

Biotech drugmaker Amgen Inc. said Tuesday that its third-quarter profit jumped 24 percent, trouncing analysts' expectations, as sales of more than a half-dozen of its drugs increased by double digits.

The strong performance in the quarter ending Sept. 30 came just before Amgen closed its $9.7 billion purchase of cancer drug maker Onyx Pharmaceuticals on Oct. 1—part of Amgen's strategy to expand beyond its medicines for easing side effects of some cancer treatments and enter the market for pricey cancer drugs.

It's also just begun joint ventures to sell colorectal cancer drug Vectibix in China and to develop and then sell five medicines in Japan. Japan is the world's second-biggest medicine market, after the U.S., and China is spending more on health care, making its huge and aging population a growth target for most pharmaceutical and biotech companies.

Amgen, which sells arthritis treatment Enbrel and Prolia for osteoporosis, said net income was $1.37 billion, or $1.79 per share, up from $1.11 billion, or $1.41 per share, a year earlier.

The Thousand Oaks, California-based company said earnings were $1.94 per share excluding one-time items, mainly costs related to acquisitions, efficiency efforts and issuing stock options. Analysts were expecting $1.76 per share.

Amgen's stock rose 79 cents to $117 in after-hours trading after rising $2.57, or 2.3 percent, to $116.21 during the regular trading session.

Amgen beat that handily due to a decline in its tax rate, a $155 million U.S. government order for Neupogen for boosting infection-fighting white blood cells, and very strong sales of nearly all its drugs.

Revenue was up 10 percent at $4.75 billion, topping the $4.6 billion analysts expected.

The company also raised the lower end of its 2013 profit forecast by a nickel and now expects $7.35 to $7.45 per share.

"We delivered excellent operating performance this quarter," chief executive Robert Bradway said in a statement. "We also delivered excellent strategic progress."

Explore further: Amgen 4Q profit drops 16 pct. on higher spending

Related Stories

Amgen 4Q profit drops 16 pct. on higher spending

January 23, 2013

Drugmaker Amgen Inc. on Wednesday posted a 16 percent drop in fourth-quarter profit, as higher costs for production, marketing, research and other items offset higher sales for many of its biologic medicines. The results ...

Generic competition cuts Merck's Q1 sales, profit

May 1, 2013

Drugmaker Merck & Co. is reporting lower first-quarter results and cutting its 2013 profit forecast by 15 cents a share. It also is announcing a huge share buyback, up to $15 billion worth of its stock.

Recommended for you

Sustaining biomedical research: Med school deans speak out

May 27, 2015

Cuts in federal support and unreliable funding streams are creating a hostile work environment for scientists, jeopardizing the future of research efforts and ultimately clinical medicine, according to leaders of the nation's ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.